24/7 Market News Snapshot 10 July, 2025 – Klotho Neurosciences, Inc. Common Stock (NASDAQ:KLTO)

July 10, 2025

DENVER, Colo., 10 July, 2025 (www.247marketnews.com) – (NASDAQ:KLTO) are discussed in this article.
Klotho Neurosciences, Inc. (KLTO) has recently experienced a remarkable uptick in market interest, with pre-market trading reflecting a significant 32.85% increase, climbing to $1.820 from a previous close of $1.370. This surge is underscored by an impressive trading volume of 5.46 million shares, signaling strong investor enthusiasm for the company’s potential. The positive market movement is particularly timely, coinciding with the important announcement that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to KLTO’s innovative gene delivery system, KLTO-202, for the treatment of Amyotrophic Lateral Sclerosis (ALS).

This Orphan Drug Designation is critical as it underscores the company’s commitment to addressing the needs of small patient populations affected by severe conditions like ALS, which impacts about 5,000 new individuals annually in the U.S. The designation provides access to numerous incentives, including tax benefits for clinical trial costs and seven years of market exclusivity post-approval, a substantial advantage in the competitive pharmaceutical landscape.

Dr. Joseph Sinkule, CEO of Klotho Neurosciences, highlighted the personal significance of this milestone, reflecting on family experiences with ALS. He stated, “This designation affirms our dedication to advancing the first gene replacement therapy aimed at halting motor neuron damage in ALS patients.” Klotho aims to revolutionize treatment approaches for ALS by leveraging the therapeutic potential of the s-KL protein at the neuromuscular junction.

As the company readies itself to initiate manufacturing processes and engage with regulatory authorities, it stands poised to pioneer transformative advancements in treating ALS and other neurodegenerative diseases. Klotho Neurosciences remains steadfast in its mission to lead breakthroughs that significantly enhance the lives of those grappling with age-related ailments. With these developments, the company’s future in neurotherapeutics appears highly promising.

Related news for (KLTO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.